Anti-Human IL-12 / IL-23 (Briakinumab Biosimilar)
Catalog #500010
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500010 | 1 mg | $200.00 | ||
| 500010 | 5 mg | $600.00 | ||
| 500010 | 20 mg | $1,400.00 |
Product Details
Briakinumab biosimilar is a recombinant fully human monoclonal IgG1 antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23). It is developed as a cost-effective alternative to the reference biologic Briakinumab, maintaining comparable efficacy, safety, and quality. This biosimilar is intended for research and potential therapeutic applications in autoimmune and inflammatory diseases, including psoriasis, rheumatoid arthritis, and inflammatory bowel diseases.
Specifications
| Clone | Briakinumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 7.4 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human IL-12 / IL-23 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |